469 related articles for article (PubMed ID: 15342423)
1. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells.
Serafini P; Carbley R; Noonan KA; Tan G; Bronte V; Borrello I
Cancer Res; 2004 Sep; 64(17):6337-43. PubMed ID: 15342423
[TBL] [Abstract][Full Text] [Related]
2. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
[TBL] [Abstract][Full Text] [Related]
3. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine.
Chang EY; Chen CH; Ji H; Wang TL; Hung K; Lee BP; Huang AY; Kurman RJ; Pardoll DM; Wu T
Int J Cancer; 2000 Jun; 86(5):725-30. PubMed ID: 10797297
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells.
Dang Y; Wagner WM; Gad E; Rastetter L; Berger CM; Holt GE; Disis ML
Clin Cancer Res; 2012 Jun; 18(11):3122-31. PubMed ID: 22510348
[TBL] [Abstract][Full Text] [Related]
5. Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice.
Nagai E; Ogawa T; Kielian T; Ikubo A; Suzuki T
Cancer Immunol Immunother; 1998 Oct; 47(2):72-80. PubMed ID: 9769115
[TBL] [Abstract][Full Text] [Related]
6. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.
Filipazzi P; Valenti R; Huber V; Pilla L; Canese P; Iero M; Castelli C; Mariani L; Parmiani G; Rivoltini L
J Clin Oncol; 2007 Jun; 25(18):2546-53. PubMed ID: 17577033
[TBL] [Abstract][Full Text] [Related]
7. Non-transmissible Sendai virus encoding granulocyte macrophage colony-stimulating factor is a novel and potent vector system for producing autologous tumor vaccines.
Inoue H; Iga M; Nabeta H; Yokoo T; Suehiro Y; Okano S; Inoue M; Kinoh H; Katagiri T; Takayama K; Yonemitsu Y; Hasegawa M; Nakamura Y; Nakanishi Y; Tani K
Cancer Sci; 2008 Nov; 99(11):2315-26. PubMed ID: 18957055
[TBL] [Abstract][Full Text] [Related]
8. Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects.
Tian H; Shi G; Yang G; Zhang J; Li Y; Du T; Wang J; Xu F; Cheng L; Zhang X; Dai L; Chen X; Zhang S; Yang Y; Yu D; Wei Y; Deng H
BMC Cancer; 2014 Jan; 14():48. PubMed ID: 24475975
[TBL] [Abstract][Full Text] [Related]
9. Induction of T-cell apoptosis in rats by genetically engineered glioma cells expressing granulocyte-macrophage colony-stimulating factor and B7.1.
Tseng SH; Chen Y; Chang CJ; Tai KF; Lin SM; Hwang LH
Clin Cancer Res; 2005 Feb; 11(4):1639-49. PubMed ID: 15746069
[TBL] [Abstract][Full Text] [Related]
10. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
11. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
[TBL] [Abstract][Full Text] [Related]
12. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma.
Sandler AD; Chihara H; Kobayashi G; Zhu X; Miller MA; Scott DL; Krieg AM
Cancer Res; 2003 Jan; 63(2):394-9. PubMed ID: 12543793
[TBL] [Abstract][Full Text] [Related]
13. Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine.
Thomas MC; Greten TF; Pardoll DM; Jaffee EM
Hum Gene Ther; 1998 Apr; 9(6):835-43. PubMed ID: 9581906
[TBL] [Abstract][Full Text] [Related]
14. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.
Kass E; Panicali DL; Mazzara G; Schlom J; Greiner JW
Cancer Res; 2001 Jan; 61(1):206-14. PubMed ID: 11196163
[TBL] [Abstract][Full Text] [Related]
15. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells.
Morales JK; Kmieciak M; Knutson KL; Bear HD; Manjili MH
Breast Cancer Res Treat; 2010 Aug; 123(1):39-49. PubMed ID: 19898981
[TBL] [Abstract][Full Text] [Related]
16. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer.
Simons JW; Jaffee EM; Weber CE; Levitsky HI; Nelson WG; Carducci MA; Lazenby AJ; Cohen LK; Finn CC; Clift SM; Hauda KM; Beck LA; Leiferman KM; Owens AH; Piantadosi S; Dranoff G; Mulligan RC; Pardoll DM; Marshall FF
Cancer Res; 1997 Apr; 57(8):1537-46. PubMed ID: 9108457
[TBL] [Abstract][Full Text] [Related]
17. Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines.
Dunussi-Joannopoulos K; Dranoff G; Weinstein HJ; Ferrara JL; Bierer BE; Croop JM
Blood; 1998 Jan; 91(1):222-30. PubMed ID: 9414288
[TBL] [Abstract][Full Text] [Related]
18. Suppressive effects on the immune response and protective immunity to a JEV DNA vaccine by co-administration of a GM-CSF-expressing plasmid in mice.
Chen H; Gao N; Fan D; Wu J; Zhu J; Li J; Wang J; Chen Y; An J
PLoS One; 2012; 7(4):e34602. PubMed ID: 22493704
[TBL] [Abstract][Full Text] [Related]
19. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
[TBL] [Abstract][Full Text] [Related]
20. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.
Machiels JP; Reilly RT; Emens LA; Ercolini AM; Lei RY; Weintraub D; Okoye FI; Jaffee EM
Cancer Res; 2001 May; 61(9):3689-97. PubMed ID: 11325840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
